DERM Alpin from November 03 to 05, 2023 in Salzburg, Austria
BIO-EUROPE from November 6 to 8, 2023 in Munich, Germany
7th Potsdam Wound Symposium on November 11, 2023 in Potsdam, Germany
06th Nuremberg Wound Congress from November 23 to 24, 2023 in Nuremberg, Germany
16th Interdisciplinary WoundCongress on November 30, 2023 in Cologne, Germany
RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected.
For the press release click here
Professor Dr. med. Karin Scharffetter-Kochanek, Dr. Christoph Ganss and Dr. Andreas Kluth from RHEACELL received the "Kooperationspreis Wissenschaft-Wirtschaft 2022" from Ulm University.
For the press release click here (only in German)
RHEACELL receives "Partners in Progress Award" from debra of America for Epidermolysis Bullosa research.
For the press release click here
It is only the second authorized "Somatic Cell Therapy Medicinal Product".
For more information click here
RHEACELL is conducting a follow-up study with highly purified stem cells for the treatment of previously incurable chronic ulcers.
For the press release click here
RHEACELL has been granted national marketing authorization in Germany (§ 4b of the German Medicinal Products Act) for its’ cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.
For the press release click here
The European Medicines Agency (EMA) has approved the pediatric investigation plan for our Epidermolysis Bullosa program, bringing us one step closer to filing for marketing authorization.
Based on convincing clinical results (I/IIa) in the indication of non-healing chronic venous ulcers (CVU), RHEACELL filed for national marketing authorization in Germany (special provisions governing advanced therapy medicinal products).
Heidelberg-based biopharmaceutical company demonstrates efficacy and safety of ABCB5-positive stem cells in CVU patients in clinical phase IIa trial.
Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.
Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.
Biopharma company completes three registered somatic cell therapy clinical trials for severe, chronic diseases.
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the FDA and the European Medicines Agency) and Fast Track Designation from the FDA for the treatment of LSCD.